Churg-Strauss syndrome and leukotriene-modifying agents

Clinical Pulmonary Medicine

Volumn 11, Issue 6, 2004, Pages 349-354

  Pagnoux, Christian ^a   Guilpain, Philippe ^a   Hauser, Thomas ^b   Mahr, Alfred ^a   Guillevin, Loïc ^a  

^a Hôpital Cochin ^*  (France)

^b Rheumatologische Universitatsklinik und Poliklinik   (Switzerland)

Author keywords

Asthma therapy; Churg Strauss syndrome; Leukotriene receptor antagonists; Montelukast; Pranlukast; Zafirlukast

Indexed keywords

AZLAIRE; MONTELUKAST; PRANLUKAST; STEROID; ZAFIRLUKAST; ZILEUTON;

ASTHMA; CARDIOMYOPATHY; CHURG STRAUSS SYNDROME; DISEASE COURSE; DRUG CONTRAINDICATION; HUMAN; NEUROPATHY; REVIEW; TREATMENT OUTCOME;

EID: 8744312793     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000145616.20285.98     Document Type: Review

References (76)

1. Churg J, Strauss L. Allergic angiitis and periarteritis nodosa. Am J Pathol. 1951;27:277-301.
2. Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984;63:65-81.
3. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78:26-37.
4. Haas C, Le Jeunne C, Choubrac P, et al. Churg-Strauss syndrome: retrospective study of 20 cases [in French]. Bull Acad Natl Méd. 2001;185:1113-1130.
5. Sehgal M, Swanson JW, DeRemee RA, et al. Neurologic manifestations of Churg-Strauss syndrome. Mayo Clin Proc. 1995;70:337-341.
6. Guillevin L, Lê Thi Huong D, Godeau P, et al. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. Br J Rheumatol. 1988;27:258-264.
7. Chumbley LC, Harrison EG Jr, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome): report and analysis of 30 cases. Mayo Clin Proc. 1977;52:477-484.
8. Reid AJ, Harrison BD, Watts RA, et al. Churg-Strauss syndrome in a district hospital. QJM. 1998;91:219-229.
9. Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. 2000; 117:708-713.
10. Loughlin JE, Cole JA, Rothman KJ, et al. Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. Ann Allergy Asthma Immunol. 2002;88:319-325.
11. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094-1100.
12. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA. 1998;279:455-457.
13. O'Byrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med. 1997;127:472-480.
14. Drazen JM. Asthma therapy with agents preventing leukotriene synthesis or action. Proc Assoc Am Physicians. 1999;111:547-559.
15. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999;340:197-206.
16. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial: Montelukast Clinical Research Study Group. Arch Intern Med. 1998;158:1213-1220.
17. Spector SL. Safety of antileukotriene agents in asthma management. Ann Allergy Asthma Immunol. 2001;86:18-23.
18. Dunn CJ, Goa KL. Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. Drugs. 2001;61:285-315.
19. Keam SJ, Lyseng-Williamson KA, Goa KL. Pranlukast: a review of its use in the management of asthma. Drugs. 2003;63:991-1019.
20. Garcia-Marcos L, Schuster A, Perez-Yarza EG. Benefit-risk assessment of antileukotrienes in the management of asthma. Drug Saf. 2003;26: 483-518.
21. Holloway J, Ferriss J, Groff J, et al. Churg-Strauss syndrome associated with zafirlukast. J Am Osteopath Assoc. 1998;98:275-278.
22. Honsinger RW. Zafirlukast and Churg-Strauss syndrome [letter]. JAMA. 1998;279:1949.
23. Knoell DL, Lucas J, Allen JN. Churg-Strauss syndrome associated with zafirlukast. Chest. 1998;114:332-334.
24. Green RL, Vayonis AG. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. Lancet. 1999;353:725-726.
25. Soy M, Ozer H, Canataroglu A, et al. Vasculitis induced by zafirlukast therapy. Clin Rheumatol. 2002;21:328-329.
26. Katz RS, Papernik M. Zafirlukast and Churg-Strauss syndrome [letter]. JAMA. 1998;279:1949.
27. Cooper SM, Libman BS, Lazarovich M. Churg-Strauss syndrome in a group of patients receiving fluticasone for asthma. J Rheumatol. 2002; 29:2651-2652.
28. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises: case 30-2000: a 25-year-old man with asthma, cardiac failure, diarrhea, and weakness of the right hand. N Engl J Med. 2000;343:953-961.
29. Kinoshita M, Shiraishi T, Koga T, et al. Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. J Allergy Clin Immunol. 1999;103:534-535.
30. Baba K, Niwa S, Yagi T, et al. Churg-Strauss syndrome during corticosteroid tapering in a patient with bronchial asthma receiving pranlukast [in Japanese]. Arerugi. 2000;49:512-515.
31. Katsura T, Yoshida F, Takinishi Y. The Churg-Strauss syndrome after pranlukast treatment in a patient not receiving corticosteroids. Ann Intern Med. 2003;139:386-387.
32. Tang MB, Yosipovitch G. Acute Churg-Strauss syndrome in an asthmatic patient receiving montelukast therapy. Arch Dermatol. 2003;139: 715-718.
33. Villena V, Hidalgo R, Sotelo MT, et al. Montelukast and Churg-Strauss syndrome [letter]. Eur Respir J. 2000;15:626.
34. Gal AA, Morris RJ, Pine JR, et al. Cutaneous lesions of Churg-Strauss syndrome associated with montelukast therapy. Br J Dermatol. 2002; 147:618-619.
35. Franco J, Artes MJ. Pulmonary eosinophilia associated with montelukast. Thorax. 1999;54:558-560.
36. Tuggey JM, Hosker HS. Churg-Strauss syndrome associated with montelukast therapy [letter]. Thorax. 2000;55:805-806.
37. Trujillo-Santos AJ, Peralta-Camisuli L, Garcia de Lucas MD, et al. Churg-Strauss syndrome associated with montelukast [letter] [in Spanish]. Med Clin (Barc). 2000;115:599.
38. Guilpain P, Viallard JF, Lagarde P, et al. Churg-Strauss syndrome in two patients receiving montelukast. Rheumatology (Oxford). 2002;41:535-539.
39. Mukhopadhyay A, Stanley NN. Churg-Strauss syndrome associated with montelukast. Postgrad Med J. 2001;77:390-391.
40. Jamaleddine G, Diab K, Tabbarah Z, et al. Leukotriene antagonists and the Churg-Strauss syndrome. Semin Arthritis Rheum. 2002;31:218-227.
41. Turvey SE, Vargas SO, Phipatanakul W. Churg-Strauss syndrome in a 7-year-old receiving montelukast and inhaled corticosteroids [letter]. Ann Allergy Asthma Immunol. 2003;90:274.
42. Donohue JF. Montelukast and Churg-Strauss syndrome [letter]. Chest. 2001;119:668.
43. th Annual Meeting of the American Academy of Allergy, Asthma and Immunology; 2000, San Diego, CA.
44. Josefson D. Asthma drug linked with Churg-Strauss syndrome [letter]. BMJ. 1997;315:330.
45. Watts RA, Carruthers DM, Scott DG. Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum. 1995;25: 28-34.
46. Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf. 1999;8:179-189.
47. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115:284-290.
48. Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients: French Cooperative Study Group for Vasculitides. Br J Rheumatol. 1997;36:1290-1297.
49. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore). 1996;75:17-28.
50. Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis: EC/BCR Project for ANCA Assay Standardization. Kidney Int. 1998;53:743-753.
51. Masi AT, Hamilos DL. Leukotriene antagonists: bystanders or causes of Churg-Strauss syndrome? Semin Arthritis Rheum. 2002;31:211-217.
52. Wechsler ME, Pauwels R, Drazen JM. Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal? Drug Saf. 1999;21:241-251.
53. Stirling RG, Chung KF. Leukotriene antagonists and Churg-Strauss syndrome: the smoking gun. Thorax. 1999;54:865-866.
54. Solans R, Bosch JA, Selva A, et al. Montelukast and Churg-Strauss syndrome. Thorax. 2002;57:183-185.
55. Weller PF, Plaut M, Taggart V, et al. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol. 2001;108:175-183.
56. Churg J, Churg A. Zafirlukast and Churg-Strauss syndrome. JAMA. 1998;279:1949-1950.
57. Churg A, Brallas M, Cronin SR, et al. Formes frustes of Churg-Strauss syndrome. Chest. 1995;108:320-323.
58. Hayashi S, Furuya S, Imamura H. Fulminant eosinophilic endomyocarditis in an asthmatic patient treated with pranlukast after corticosteroid withdrawal [letter]. Heart. 2001;86:e7.
59. Lobel H, Machtey I, Eldror MY. Pulmonary infiltrates with eosinophilia in an asthmatic patient treated with disodium cromoglycate [letter]. Lancet. 1972;2:1032.
60. Bili A, Condemi JJ, Bottone SM, et al. Seven cases of complete and incomplete forms of Churg-Strauss syndrome not related to leukotriene receptor antagonists. J Allergy Clin Immunol. 1999;104:1060-1065.
61. Lipworth BJ, Wilson AM. Montelukast and Churg-Strauss syndrome [letter]. Thorax. 2001;56:244.
62. Priori R, Tomassini M, Magrini L, et al. Churg-Strauss syndrome during pregnancy after steroid withdrawal [letter]. Lancet. 1998;352:1599-1600.
63. Le Gall C, Pham S, Vignes S, et al. Inhaled corticosteroids and Churg-Strauss syndrome: a report of five cases. Eur Respir J. 2000;15: 978-981.
64. Pagnoux C, Cohen P, Mahr A, et al. Treatment of Churg-Strauss syndrome with poor prognosis factor(s): results of a prospective randomized multicenter trial comparing corticosteroids and 6 vs. 12 pulses of cyclophosphamide [abstract]. Arthritis Rheum. 2003;48:S-661.
65. Sabadell C, Jolis R, Canalias J. Churg-Strauss syndrome associated with montelukast therapy [letter] [in Spanish]. Med Clin (Barc). 2001;117: 159.
66. Sabio JM, Jimenez-Alonso J, Gonzalez-Crespo F. More about Churg-Strauss syndrome and montelukast treatment [letter]. Chest. 2001;120: 2116.
67. Wechsler M. Churg-Strauss syndrome with montelukast [letter]. Thorax. 2001;56:417.
68. Stoloff S, Stempel DA. Churg-Strauss syndrome: is there an association with leukotriene modifiers? Chest. 2000;118:1515-1516.
69. Mathur S, Dooley J, Scheuer PJ. Quinine induced granulomatous hepatitis and vasculitis. BMJ. 1990;300:613.
70. Imai H, Nakamoto Y, Hirokawa M, et al. Carbamazepine-induced granulomatous necrotizing angiitis with acute renal failure. Nephron. 1989;51:405-408.
71. Dietz A, Hubner C, Andrassy K. Macrolide antibiotic-induced vasculitis (Churg-Strauss syndrome) [in German]. Laryngorhinootologie. 1998;77: 111-114.
72. Finkel TH, Hunter DJ, Paisley JE, et al. Drug-induced lupus in a child after treatment with zafirlukast (Accolate®). J Allergy Clin Immunol. 1999;103:533-534.
73. Lipworth BJ. Leukotriene-receptor antagonists. Lancet. 1999;353:57-62.
74. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med. 1994;121:684-697.
75. Henderson WR Jr. Role of leukotrienes in asthma. Ann Allergy. 1994; 72:272-278.
76. Meghjee SPL, White JS. Montelukast and Churg-Strauss syndrome [letter]. Thorax. 2001;56:244.